diagnost tool
unit contract acla lawsuit mark
catalyst posit ndr buy pt
privileg host investor meet execut
director ir shawn bevec despit rate cut pama drag view
quest underappreci larg cap cash cow well posit consolid lab
particularli hospit lab market competit edg
lh view share trade rev street adj
ep valuat level view attract pay dividend yield note
trade peak ntm ep june rais pt
use multipl adj ep
contract repres possibl near-term posit catalyst fate
contract exclus labcorp set expir end
topic came meet remain activ dialogu
execut optum unit well execut highest level
lh may renew exclus deal sens grow
likelihood lab contract open lh well believ
stock correctli price possibl outcom lack visibl specif
impact expect street volume/rev estim rise play
lh flip flop aet contract think
possibl indic contract aet contract multipl year
believ unlik aet contract flip-flop larg lab
provid think like outcom aet contract open
lab lab negoti renew respect larg health plan
anyth good come pama believ ye
wall street shot ask question later pama see silver line
negoti price increas two major commerci payor previous
price weight median feel good plan
expect rate cut alreadi low-cost lab provid feel good
 pipelin like expand larg number lab feel actual pinch rate
cut realiz put sale prudent believ lab
better posit consolid market target cash flow
op expect acceler asset purchas particularli
lab feel sting reimburs cut
acla lawuit expect updat next month around mid-april cautious
optimist may see inclus hospit outreach lab rate weight
median formula next data collect period could provid relief
consum oper safeway store near initi goal
open locat store myquest mobil app use
peopl y/i still small also overflow test
consum genom leader ancestri dna think grow
dividend tax reform recent rais dividend
year yield also major winner us tax reform target
reinvest save refresh patient
servic center launch advanc test hire genet counselor
price close busi march
largest clinic laboratori us
focus routin gene-bas esoter test
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
unit contract acla lawsuit
mark catalyst posit
ndr reiter buy rais pt
privileg host investor meet execut
director ir shawn bevec despit rate cut pama estim drag
view quest underappreci larg cap cash cow well posit
consolid lab particularli hospit lab market
competit edg lh view share trade rev
street adj ep valuat level view attract pay
dividend yield note trade peak ntm ep june
rais pt use multipl
adj ep
contract repres possibl near-term posit catalyst fate
contract exclus labcorp set expir end
topic came recent investor meet remain
activ dialogu execut optum unit well execut
highest level lh may renew exclus deal sens
grow likelihood exclus lab contract lh open
lh well believ stock correctli price
possibl outcom lack visibl specif impact expect street
volume/rev estim rise play quest point
meet present larg book busi unit out-
of-network bottom line still believ fairli meaning beneficiari
open contract includ lh particularli volum
clear open contract would benefit dgx revenue/requisit
believ would benefit volum revenu
lh flip flop aet contract think
possibl indic contract aet contract multipl
year believ unlik aet contract flip-flop
larg lab provid think like outcom aet
contract open lab lab negoti renew
anyth good come pama believ ye
wall street shot ask question later pama see silver line
negoti price increas two major commerci payor previous
price weight median feel good plan
expect rate cut alreadi low-cost lab provid feel good
 pipelin like expand larg number lab feel actual pinch
rate cut realiz put sale prudent believ
lab better posit consolid market target cash
flow op expect acceler asset purchas particularli
lab feel sting reimburs cut
acla lawsuit impact pama cut quest deriv total
rev clinic lab fee schedul clf quest
estim cut clf pama expect
cut rise quest indic investor
meet expect updat acla vs lawsuit sometim next
month mid-april cautious optimist may see inclus
hospit outreach lab rate weight median formula next data
buy unchang target price march
diagnost tool
collect period happen could provid relief quest well
lh year reimburs revenue/requisit
revenu chang expect base case statu quo hold
believ stock price statu quo bottom line think chang
statu quo lawsuit might propel stock lh rise
market would assign higher multipl stock multi-year
materi major reimburs overhang stock view
dividend tax reform recent rais dividend
yield also major winner us tax reform target
tax rate result estim
save save expect drop
sharehold re-invest employe
busi primarili refresh number patient servic
center launch advanc esoter test present make
billion revenu higher profit mix hire genet
counselor quest reinvest larg focus technolog improv
enhanc user experi consum initi drive stronger organ
volum new higher valu esoter test earmark
award non-bonu elig employe receiv bonu
expect deploy back busi
growth help remind earn
call initi strong revenu guid y/i
adj ep estim unchang estim call
rev model rev
model adj ep estim
exclud acquisit announc yet typic accret
remind complet acquisit ad point
revenu growth guid assum point growth
much growth contribut growth
far earn accret goe acquir lab ie hospit outreach lab
indic busi acquir oper high singl digit
oper margin time move busi close mid
high teen level oper margin
long-term financi target intact meet reiter expect
grow top line mid-to-high single-digit
earn growth quest lt target contempl growth
organ growth new partnership hospit health plan improv
health plan access get back network return high-singl
digit growth esoter test current grow mid-singl digit consum
continu drive cost busi
save persist beyond dgx invigor program
achiev cost save year-end expect cost
save beyond believ best class compani shave
costs/year would impli specif
quantifi cost reduct target beyond think good amount
wood chop sever year compani continu improv lot
process materi chang year despit great technolog
advanc outsid lab industri includ addit consolid
system well facil requisit process today done
platform e-en autom effort continu execut exist
cost save initi reduc million annual bad debt
buy unchang target price march
diagnost tool
minut per patient reduc time per patient minut would
move needl
today requisit come via electron order indic
paper requisit cost electron order natur
expect grow order come electron state
particular goal time-frame
mobil side dgx myquest mobil app allow custom book
appoint check electron link payment option myquest
use nearli user increas user
hospit outreach lab remain plenti market favor target
quest priorit market share gain hospit much larger pie
refer lab quest outreach strategi involv purchas hospit outreach
lab sign profession laboratori servic pl agreement provid refenc
lab test hospit hospit continu staff lab
believ hospit system mani less sophist
lh like havent quantifi yet felt impact pama impact
begin sink expect hospit system either approach
will collabor
despit leadership posit billion refer lab market
overal us lab pie given success traction partner
hospit pie acquir hospit outreach believ
earli day hospit strategi
figur believ pama tax reform posit target smaller less-sophist lab
buy unchang target price march
diagnost tool
figur target hospit outreach lab opportun profession lab servic agreement
consum lh make larger invest better engag directli
consum frankli make sens compani like bid
similar contract oper safeway store near initi goal
expect hit expect continu expand retail
presenc safeway store next sever year addit quest open
locat store expect number increas though
dont visibl mani myquest mobil applic
use peopl y/i still small
take step get closer consum
quest patient servic center psc retail locat like
safeway psc locat strip mall offic build
safeway origin carv retail space therano abl
swoop therano oust psc staf
phlebotomist good candid move retail locat roughli
dgx test volum come patient servic center vs clinician
indic pay slightli less rent retail locat psc
expens attribut labor
data technolog enabl benefit consum
increasingli focus popul health name enabl health plan
provid better assess popul close gap care focu
connect patient phone home retail store conveni
set announc earli februari complet acquisit mobil
medic examin servic medxm provid home-bas health risk
assess relat servic hold substanti valu roughli
buy unchang target price march
diagnost tool
billion lab test data point system expect time look seek
monet data greater way
benefit rise trend consum genet test ye
contract access overflow test consum genom test leader
ancestri dna expect grow next-gener sequenc leader
buy indic consum genotyp test
perform nearli increas know
ancestri sold test kit black friday cyber monday alon
estim ancestri sold million test kit sinc
launch estim ancestri achiev custom end
estim direct-to-consum dtc test achiev driven
increas ancestri well upstart helix among other
new lab futur come new jersey
quest break ground new lab teterboro new jersey larger
marlborough lab futur current largest autom lab
world understand see takeaway lab tour
marlboro quest manag last spring/summ quest plan tear
older teterboro nj lab replac larger version marlborough
lab wherea quest use exist build marlborough lab expect
build teterboro lab ground provid estim cost
build lab expect multi-year project provid
capital-expenditure guid expect like achiev cost synergi
consolid real estat footprint quantifi anyth
collabor quintil squar solut optum perform well
quest quintil sign jv aim help biopharma custom bring
new drug therapi market support precis medicin quintil own
largest custom quest go win new busi quest
success maintain key custom servic sub-scal clinic trial
said believ fair say quintil jv rel small scope
quest nearli year revenu manag collabor optum
subsidiari unitedcar quest seen improv cash
collect reduct percentag denial sit low
double-digit optum enabl sync payor mirror
server help adjud claim current collabor servic six health
plan quest/optum intend add addit plan quest bad
debt expens histor hover around
expand capabl come
quest announc earli februari partnership offer
compani ngs-base oncomin dx target test companion diagnost panel
non-smal cell lung cancer quest partnership earn earli access
thermo pipelin novel platform assay assist develop
oncomine-brand solut clinic biopharma applic dgx
custom express interest target sequenc nipt test tumor
sequenc hereditari cancer test
cvs/aetna merger noth sweat dgx perspect
quest indic investor meet cvs/aetna merger impact
dgx agreement aet manag believ cvs/aet deal affirm dgx
retail strategi move closer patient recal oper patient servic
center safeway store earli jv store today
buy unchang target price march
diagnost tool
figur trade consensu adj ep stock trade long ago
buy unchang target price march
diagnost tool
figur trade nearli consensu revenu estim
buy unchang target price march
diagnost tool
canaccord genuiti estim compani report
buy unchang target price march
diagnost tool
canaccord genuiti estim compani report
buy unchang target price march
diagnost tool
